Article
Nitroxoline resistance is associated with significant fitness loss and diminishes in vivo virulence of Escherichia coli
8 Dec 2023
Abstract excerpt
ABSTRACT Nitroxoline (NTX) is an antibiotic approved for the treatment of uncomplicated urinary tract infections (UTIs) caused by Enterobacteriaceae like Escherichia coli , and it has been on the market for more than 50 years. Despite being in use longer than several other clinically relevant antibiotics, the resistance of clinical isolates against NTX has not evolved significantly. To better understand this...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
